Y Intercept Hong Kong Ltd acquired a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 28,023 shares of the medical research company’s stock, valued at approximately $5,604,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NTRA. Leonteq Securities AG grew its position in shares of Natera by 23.3% during the 1st quarter. Leonteq Securities AG now owns 1,815 shares of the medical research company’s stock valued at $363,000 after acquiring an additional 343 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of Natera by 36.9% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 43,550 shares of the medical research company’s stock worth $8,710,000 after purchasing an additional 11,750 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in Natera in the first quarter valued at approximately $1,306,000. IFM Investors Pty Ltd lifted its stake in Natera by 3.5% in the first quarter. IFM Investors Pty Ltd now owns 26,024 shares of the medical research company’s stock valued at $5,205,000 after purchasing an additional 889 shares during the last quarter. Finally, Harbor Investment Advisory LLC grew its holdings in Natera by 77.6% during the first quarter. Harbor Investment Advisory LLC now owns 3,576 shares of the medical research company’s stock valued at $715,000 after purchasing an additional 1,563 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have issued reports on NTRA. William Blair began coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. BTIG Research set a $275.00 price target on Natera and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Robert W. Baird set a $265.00 price objective on Natera in a report on Friday, May 8th. The Goldman Sachs Group began coverage on Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective on the stock. Finally, Guggenheim upped their price objective on shares of Natera from $270.00 to $290.00 and gave the company a “buy” rating in a report on Monday, June 29th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $260.33.
Insider Activity at Natera
In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares of the company’s stock, valued at $24,035,465.29. The trade was a 27.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rowan E. Chapman sold 2,964 shares of Natera stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the transaction, the director directly owned 3,124 shares of the company’s stock, valued at $677,220.72. The trade was a 48.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 175,872 shares of company stock worth $38,808,996 in the last 90 days. 5.05% of the stock is owned by company insiders.
Natera Price Performance
NASDAQ:NTRA opened at $279.32 on Friday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $279.63. The stock’s fifty day moving average price is $219.79 and its two-hundred day moving average price is $217.32. The company has a market cap of $40.00 billion, a P/E ratio of -171.36 and a beta of 1.51.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
